血必净和乌司他丁单独用药及联合用药对多发伤患者的有效性分析  

Analysis of the efficacy of Xuebijing and ulinastatin alone and in combination for patients with multiple injuries

作　　者：张文媛 ZHANG Wenyuan(Department of Teaching,Fuzhou Second Hospital,Fujian,Fuzhou 350000,China)

机构地区：[1]福州市第二医院教学部,福建福州350000

出　　处：《中国医药科学》2023年第18期73-76,93,共5页China Medicine And Pharmacy

摘　　要：目的观察血必净和乌司他丁单独用药及联合用药对多发伤患者的疗效及可能的作用机制。方法回顾性连续纳入2021年1月至2022年4月福州市第二医院重症医学科收治的77例多发伤患者,根据用药情况分为血必净组、乌司他丁组和联合用药组。通过检索病历数据库,获取患者人口学信息、疾病评分表、实验室指标等资料。比较三组患者疾病特征的差异,同时比较治疗前后三组患者的炎症指标、营养学评估、病情严重程度评分等的变化。结果联合组总住院时程、机械通气时程均短于血必净组、乌司他丁组,差异有统计学意义(P<0.05),重症监护室(ICU)滞留时程比较,差异无统计学意义(P>0.05)。治疗后,联合组在白细胞计数(WBC)、超敏C-反应蛋白(hs-CRP)、降钙素原(PCT)低于血必净组、乌司他丁组,差异有统计学意义(P<0.05);联合组淋巴细胞百分比、白蛋白水平高于血必净组、乌司他丁组,差异有统计学意义(P<0.05),肌酐水平比较,差异无统计学意义(P>0.05)。联合组急性生理与慢性健康评分(APACHEⅡ评分)、序贯器官衰竭估计评分(Sofa评分)低于血必净组、乌司他丁组,差异有统计学意义(P<0.05)。结论血必净联合乌司他丁治疗多发伤能够有效地缩短围术期指标,减轻炎症反应的同时提高自身的营养状态,值得推广。Objective To observe the therapeutic effect and possible mechanism of Xuebijing and ulinastatin alone as well as in combination on patients with multiple injuries.Methods A retrospective study was conducted on 77 patients with multiple injuries admitted to the Department of Critical Care Medicine of Fuzhou Second Hospital from January 2021 to April 2022.They were divided into a Xuebijing group,a ulinastatin group,and a combined medication group based on their medication status.By searching the medical record database,we obtained patients’demographic data,disease scoring tables,laboratory indicators,etc.To compare the differences in disease characteristics among the three groups.At the same time,the changes in inflammatory indicators,nutritional assessments,and severity scores of the three groups before and after treatment were compared.Results The total hospitalization duration and mechanical ventilation duration of the combined medication group were shorter than those of the Xuebijing group and the ulinastatin group,with statistically significant differences(P<0.05),while there was no statistically significant difference in intensive care unit(ICU)retention duration(P>0.05).After treatment,the inflammatory indexes such as white blood cell count(WBC),hypersensitivity C-reactive protein(hs-CRP)and procalcitonin(PCT)in the combined medication group were significantly lower than those in the Xuebijing group and the ulinastatin group,with statistically significant differences(P<0.05).Lymphocyte percentage and albumin indicators of the combined medication group were significantly higher than those in the Xuebijing group and the ulinastatin group,with statistically significant differences(P<0.05).However,there was no statistically significant difference in creatinine level(P>0.05).The acute physiological and chronic health evaluation scores(APACHEⅡ)and sequential organ failure estimation score(Sofa)of the combined medication group were significantly lower than those of the Xuebijing group and the ulinastatin group,

关 键 词：血必净 乌司他丁 多发伤 持续炎症-免疫抑制-分解代谢综合征 

分 类 号：R641[医药卫生—外科学]